These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Experimental use and the Orphan Drug Act: a biotechnology conundrum. Koivuniemi PJ Nat Biotechnol; 1996 Apr; 14(4):511-2. PubMed ID: 9630930 [No Abstract] [Full Text] [Related]
4. The Orphan Drug Act: an engine of innovation? At what cost? Rohde DD Food Drug Law J; 2000; 55(1):125-43. PubMed ID: 12322720 [No Abstract] [Full Text] [Related]
5. Prescription for the Orphan Drug Act: the impact of the FDA's 1992 regulations and the latest congressional proposals for reform. Clissold DB Food Drug Law J; 1995; 50(1):125-47. PubMed ID: 10342989 [No Abstract] [Full Text] [Related]
6. The routes to orphan drug designation--our recent experience at the FDA. Lev D; Thorat C; Phillips I; Thomas M; Imoisili MA Drug Discov Today; 2012 Feb; 17(3-4):97-9. PubMed ID: 22210120 [No Abstract] [Full Text] [Related]
7. Health care policy. Reforming off-label promotion to enhance orphan disease treatment. Liang BA; Mackey T Science; 2010 Jan; 327(5963):273-4. PubMed ID: 20075234 [No Abstract] [Full Text] [Related]
8. EMEA approves OGS drug rejected by FDA. Mitchell P Nat Biotechnol; 2002 Sep; 20(9):858-9. PubMed ID: 12205490 [No Abstract] [Full Text] [Related]
9. Do investors value the FDA orphan drug designation? Miller KL Orphanet J Rare Dis; 2017 Jun; 12(1):114. PubMed ID: 28629392 [TBL] [Abstract][Full Text] [Related]
10. The Orphan Drug Act Revisited. Thomas S; Caplan A JAMA; 2019 Mar; 321(9):833-834. PubMed ID: 30768155 [No Abstract] [Full Text] [Related]
11. Incentives for drug development--the curious case of colchicine. Kesselheim AS; Solomon DH N Engl J Med; 2010 Jun; 362(22):2045-7. PubMed ID: 20393164 [No Abstract] [Full Text] [Related]
12. FDA launches priority vouchers for neglected-disease drugs. Waltz E Nat Biotechnol; 2008 Dec; 26(12):1315-6. PubMed ID: 19060849 [No Abstract] [Full Text] [Related]
13. The Orphan Drug Act. Should it be changed? Sanders CA Arch Intern Med; 1993 Dec; 153(23):2623-5. PubMed ID: 8250658 [No Abstract] [Full Text] [Related]
15. Characteristics of orphan drug applications that fail to achieve marketing approval in the USA. Heemstra HE; Leufkens HG; Rodgers RP; Xu K; Voordouw BC; Braun MM Drug Discov Today; 2011 Jan; 16(1-2):73-80. PubMed ID: 21094692 [TBL] [Abstract][Full Text] [Related]
16. Orphan drug regulations. Final rule. Food and Drug Administration, HHS Fed Regist; 2013 Jun; 78(113):35117-35. PubMed ID: 23767079 [TBL] [Abstract][Full Text] [Related]
17. Regulators adopt more orphan drugs. Reardon S Nature; 2014 Apr; 508(7494):16-7. PubMed ID: 24695293 [No Abstract] [Full Text] [Related]
18. Berlex continues legal challenge to FDA over MS drug. Glaser V Nat Biotechnol; 1996 Jul; 14(7):811-2. PubMed ID: 9630997 [No Abstract] [Full Text] [Related]
19. The problem of orphan drugs. Ferner RE; Hughes DA BMJ; 2010 Nov; 341():c6456. PubMed ID: 21081597 [No Abstract] [Full Text] [Related]
20. Orphan drugs and orphan tests in the USA. Thoene JG Community Genet; 2004; 7(4):169-72. PubMed ID: 15692190 [No Abstract] [Full Text] [Related] [Next] [New Search]